Last reviewed · How we verify
Standard-of-care Antiretroviral therapy
Standard-of-care Antiretroviral therapy is a Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors) Small molecule drug developed by Medical Research Council. It is currently FDA-approved for HIV-1 infection (treatment and prevention), AIDS (acquired immunodeficiency syndrome).
Standard-of-care antiretroviral therapy suppresses HIV replication by targeting viral enzymes (reverse transcriptase, protease, integrase) and entry mechanisms to reduce viral load and restore immune function.
Standard-of-care antiretroviral therapy suppresses HIV replication by targeting viral enzymes (reverse transcriptase, protease, integrase) and entry mechanisms to reduce viral load and restore immune function. Used for HIV-1 infection (treatment and prevention), AIDS (acquired immunodeficiency syndrome).
At a glance
| Generic name | Standard-of-care Antiretroviral therapy |
|---|---|
| Sponsor | Medical Research Council |
| Drug class | Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors) |
| Target | HIV reverse transcriptase, HIV protease, HIV integrase, HIV envelope glycoproteins (CCR5/CXCR4 co-receptors) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Antiretroviral therapy typically combines multiple drug classes that work synergistically to block different stages of the HIV life cycle. Modern regimens usually include nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), or entry inhibitors. This multi-drug approach prevents viral replication, allows CD4+ T-cell recovery, and reduces transmission risk.
Approved indications
- HIV-1 infection (treatment and prevention)
- AIDS (acquired immunodeficiency syndrome)
Common side effects
- Nausea and gastrointestinal disturbance
- Headache
- Fatigue
- Lipodystrophy (fat redistribution)
- Peripheral neuropathy
- Hepatotoxicity
- Lactic acidosis (rare)
- Immune reconstitution inflammatory syndrome (IRIS)
Key clinical trials
- Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy (PHASE1)
- Opioid, HIV and Immune System (PHASE4)
- Evaluation of Multiple Interventions to Improve HIV Treatment Outcomes Among People Who Inject Drugs in India (NA)
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
- A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV (PHASE1)
- HIV Self-testing for Partners of HIV-uninfected Postpartum Women (NA)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- The Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard-of-care Antiretroviral therapy CI brief — competitive landscape report
- Standard-of-care Antiretroviral therapy updates RSS · CI watch RSS
- Medical Research Council portfolio CI
Frequently asked questions about Standard-of-care Antiretroviral therapy
What is Standard-of-care Antiretroviral therapy?
How does Standard-of-care Antiretroviral therapy work?
What is Standard-of-care Antiretroviral therapy used for?
Who makes Standard-of-care Antiretroviral therapy?
What drug class is Standard-of-care Antiretroviral therapy in?
What development phase is Standard-of-care Antiretroviral therapy in?
What are the side effects of Standard-of-care Antiretroviral therapy?
What does Standard-of-care Antiretroviral therapy target?
Related
- Drug class: All Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors) drugs
- Target: All drugs targeting HIV reverse transcriptase, HIV protease, HIV integrase, HIV envelope glycoproteins (CCR5/CXCR4 co-receptors)
- Manufacturer: Medical Research Council — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection (treatment and prevention)
- Indication: Drugs for AIDS (acquired immunodeficiency syndrome)
- Compare: Standard-of-care Antiretroviral therapy vs similar drugs
- Pricing: Standard-of-care Antiretroviral therapy cost, discount & access